Join your specific topic of interest based on breast subtype. Here an easy algorithm based on what treatment received. #bcsm 11:30 ET eventbrite.com/e/2022-2023-em…

Join the EMBRACE Metastatic Breast Cancer Forum which is now ongoing! Wonderful place for patients to learn about breast cancer and new therapies!

Nancy Lin, MD Dana-Farber’s Breast Oncology Center

…eforumseries_2022-2023.eventbrite.com

JUST IN: U.S. FDA approves to futibatinib (20 mg/d) in metastatic intrahepatic cholangiocarcinoma w/FGFR2 gene fusions/rearrangements. ORR was 42% in TAS-120-101 trial with top AEs: nail toxicity, MSK pain/GI.

ASCO OncoAlert

This is the first time we will be walking again as IBC Team since the pandemic. Please join us if you can!

Join us for the EMBRACE #MetastaticBreastCancer Virtual Forum Series on October 1st. A series of free online educational programs for patients, families, and loved ones. To receive email updates about upcoming events, please email [email protected].
ms.spr.ly/6017jtpFZ

Join Antonio Giordano, MD PhD and I discuss NEW standards of care in metastatic TNBC and exciting ongoing trials.

Specifically for patients, families/ loved ones or anyone interested.

Drs. Antonio Giordano (Antonio Giordano, MD PhD) and Sarah Sammons (@drsarahsam) discuss updates in research and treatment for triple negative #MBC at the EMBRACE #MetastaticBreastCancer Virtual Forum.

Sat October 1, 2022 | 11:30 a.m. – 12:30 p.m. ET
Register: ms.spr.ly/6017jtpFZ

We can finally complete the table with all results (PFS and OS) from the CDK4/6 inhibitors phase III trials in HR+/HER2- MBC 👇🏽
OS in Paloma-2 was the only outcome did not meet significant difference 🪄🤨

“stubborn and determined, and nothing much happens good in life without both of those things!” a mentor #mentorship #mentoring

CDK4/6i resistance in ER+ breast cancer ⁦Nature Communications⁩

ER+/PAM50 Basal-like biology predicts lack of benefit from CDK4/6i

ESCAT+OncoKB take a look at the accumulated evidence of this biomarker

work led by ⁦⁦Violeta Serra⁩ nature.com/articles/s4146…

Amazing work from ⁦Vall d'Hebron⁩ on mechanism of resistance to CDK4/6i. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer | Nature Communications nature.com/articles/s4146…

Neoadjuvant Durvalumab Improves Survival in Early TNBC Independent of Pathological Complete Response. Time to revisit pCR as primary and solo endpoint for IO neaoadjuvant trials? Comment 👇🏼prac.co/l/2lkj6ynk via PracticeUpdate

In HER2+ #bcsm brain mets, multiplex immunofluorescence highlighted a negative prognostic role of PD-1/PD-L1 interaction: is there a role for CPI combination with anti-Her2 Abs for patients with HER2+ brain mets? Stay tuned Nancy Lin, MD

The Complete Federico Fellini - Harvard Film Archive - cannot miss this ⁦Paolo Tarantino⁩ ⁦Dario Trapani⁩ ⁦Hal Burstein, MD⁩ kick off tomorrow night Friday at 7pm ‘And the ship sails on’ harvardfilmarchive.org/programs/the-c…

!! 🧠 important reminder #bcsm brain metastasis :
when whole brain radiation (WBRT) is recommended, Hippocampal Avoidance (HA) field plus oral Memantin are associated with less neurocognitive deterioration Nancy Lin, MD Harvard Medical School Breast Cancer Horizon 2022 Course.

Excellent review by Dr. Isakoff of HER2+ metastatic #breastcancer at Harvard Medical School 2022 New Horizons Current Controversies Course. Recap slide on approach to therapy for HER2+ #MBC #bcsm

Super star APP Elahe Salehi DNP presenting on scalp cooling - she is also leading a trial looking at efficacy of scalp cooling with novel agents (including TDXd & Sacituzumab) for pts with MBC
Harvard Medical School Dana-Farber’s Breast Oncology Center #bcsm

In the CPS-10 subgroup, the median overall survival was 23.0 months in the 1st-line pembrolizumab–chemotherapy group and 16.1 months in the placebo–chemotherapy group (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.55 to 0.95; two-sided P=0.0185 #tnbc #bcsm

Stamattina ho incontrato Vincenzo, pastore in carica di capre nelle montagne Lucane. Vincenzo è molto più saggio dei 945 e passa individui in carica per governare questa nazione 🇮🇹 #poveraItalia #capreeignoranti Vittorio Sgarbi